Additionally, verapamil can treat non‐alcoholic fatty liver disease by inhibiting the TXNIP/NLRP3 pathway and reducing the level of IL‐1β and IL‐18 to attenuate hepatic metaflammation.10 This evidence concerns the gene TXNIP and metabolic dysfunction-associated steatotic liver disease.